DPI developer Iconovo announced that the company’s ICOcap capsule-based dry powder inhaler ICOcap is now CE marked for use in clinical trials. The ICOcap inhaler is available from the Stevanato Group, which signed a manufacturing, sales, and distribution agreement for the inhaler with Iconovo in 2018.
Iconovo CEO Johan Wäborg commented, “Getting the CE certification mark for ICOcap takes Iconovo and Stevanato one step closer to commercial sales of this uniquely designed capsule inhaler. The inhaler can now be sold for use in clinical trials. This is not only of importance for Europe but also for the rest of the world since the CE marking globally is considered as a sign of quality.”
In October 2019, Iconovo announced that it was developing a new DPI platform called ICOpre for generic versions of Ellipta products. The next month, the company announced a collaboration with Crystec for development of DPIs using Crystec’s particle engineering technology. In May 2020, Iconovo announced that Amneal would take over development of a generic version of Symbicort delivered via Iconovo’s multi-dose ICOres inhaler.
Read the Iconovo press release.
